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ABSTRACT 20 
Candida albicans is known for its ability to form biofilms – communities of 21 
microorganisms embedded in an extracellular matrix developing on different22 
surfaces. Biofilms are highly tolerant to antifungal therapy. This phenomenon has 23 
been partially explained by the appearance of so-called persister cells, phenotypic 24 
variants of wild-type cells, capable of surviving very high concentrations of 25 
antimicrobial agents. Persister cells in C. albicans were found exceptionally in26 
biofilms while none were detected in planktonic cultures of this fungus. Yet, this topic 27 
remains controversial as others could not observe persister cells in biofilms formed 28 
by the C. albicans SC5314 laboratory strain. Due to ambiguous data in the literature, 29 
this work aimed to re-evaluate the presence of persister cells in C. albicans biofilms. 30 
We demonstrated that isolation of C. albicans “persister cells” as described 31 
previously was likely to be the result of survival of biofilm cells that were not reached 32 
by the antifungal. We tested biofilms of SC5314 and its derivatives, as well as 95 33 
clinical isolates, using an improved protocol, demonstrating that persister cells are 34 
not a characteristic trait of C. albicans biofilms. Although some clinical isolates are 35 
able to yield survivors upon the antifungal treatment of biofilms, this phenomenon is 36 
rather stochastic and inconsistent.  37 
38 
39 
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INTRODUCTION 40 
The yeast Candida albicans is a commensal of humans but also one of the most 41 
prevalent fungal pathogens, responsible for superficial infections as well as life- 42 
threatening systemic infections (1). C. albicans is recognized for its ability to form 43 
biofilms that are most frequently associated with nosocomial infections, particularly in44 
immunocompromised patients. 45 
C. albicans biofilms are communities of microorganisms with a complex structure46 
composed of different cell types embedded in an extracellular matrix (2–4). They47 
develop on different types of surfaces, either living or inert, and are characterized by 48 
their high tolerance to antifungals. The latter can result from the properties of the49 
extracellular matrix that can serve as a trap for drug molecules (5–7). An additional 50 
source of antifungal tolerance has been proposed to result from the occurrence in51 
biofilms of so-called persister cells, a subpopulation of phenotypic variants of wild-52 
type cells, capable of surviving concentrations of antimicrobial agents well above the 53 
Minimal Inhibitory Concentration (MIC) (8). Persister cells were first described in 54 
bacterial cultures as a drug tolerant subpopulation, that upon removal of the55 
antimicrobial agent gave rise to a new population of susceptible cells (9). Persisters 56 
are known to be genetically identical to the rest of the population, thus persistence is 57 
a non-inherited trait (10–12). 58 
In the clinical setting, persisters are usually associated with relapse of infections and 59 
with the development of chronic infections. For bacterial persisters, several 60 
mechanisms and pathways involved in their development have been described (13). 61 
In 2006, LaFleur et al. have presented the first report of persister cells in biofilms of 62 
C. albicans, which could contribute to biofilm tolerance to antifungals (8). In their63 
paper, the authors have reported that C. albicans exhibit a biphasic killing curve, 64 
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when exposed to the antifungals such as amphotericin B (AMB), chlorhexidine or the65 
combination of both. This phenomenon is explained by the presence of a multidrug-66 
tolerant subpopulation of persister cells within a biofilm, while planktonic cultures of 67 
C. albicans were found to be devoid of persisters. Notably, the experiments for this 68 
study were performed using in vitro biofilm model of C. albicans, developed in69 
polystyrene 96-well plates. Following this work and relying on the protocol for70 
persister cells isolation described therein (8), persister cells in C. albicans biofilms 71 
were described by a few other groups (14–16). However, later work by the Douglas 72 
group showed that not all Candida species and strains were able to form persister73 
cells in laboratory-grown biofilms (17). This was in particular the case for C. albicans 74 
strain SC5314 (18), the parental strain of almost all C. albicans strains used for75 
functional genomics and molecular genetics studies. Unlike in the previously76 
mentioned papers (8, 14–16), the protocol Al-Dhaheri and Douglas (17) used for 77 
persisters isolation involved growing biofilms on silicone discs followed by their 78 
immersion into an antifungal solution. As the topic of C. albicans persister cells 79 
remains controversial, the main objective of this work was to re-evaluate their 80 
occurrence in in vitro-grown C. albicans biofilms. 81 
82 
METHODS 83 
Strains and growth conditions 84 
In this study we used 3 reference strains (listed in Table 1) and a set of 95 C. 85 
albicans, 3 C. tropicalis and 3 C. parapsilosis clinical isolates (Table S1). 86 
Yeast precultures were grown overnight in YPD (1% yeast extract, 2% peptone, 2% 87 
glucose) with shaking at 30oC.  88 
5 
Biofilms were grown either in RPMI 1640 medium with L-glutamine (buffered with 5089 
mM HEPES), as described in (8) and (20), or in GHAUM medium (SD supplemented 90 
with 2% glucose and 1 mg/mL histidine, 1 mg/mL arginine, 0.02 mg/mL uridine and 2 91 
mg/mL methionine (21)).  92 
Resistance was checked on solid YNG (6,7 g/L yeast nitrogen base without amino93 
acids and with ammonium sulfate, 2% glucose and 2% agar) supplemented with 10 94 
µg/mL AMB. 95 
96 
Biofilm growth and persister cells isolation  97 
To assess persister cell appearance in biofilms we used two protocols adapted either 98 
from (8) or (14). The first protocol uses 96-well plates and the biofilms are grown in 99 
RPMI. In the second protocol the biofilms are grown in 24-well plates but using 100 
GHAUM medium instead of YNB. 101 
Biofilm growth 102 
Overnight cultures were washed in sterile 1x PBS and diluted in the corresponding 103 
medium to OD600 0.3. Either 100 µL or 1 mL of cells in the 96-well plate or the 24-well 104 
plate, respectively, were allowed to adhere for 1.5 h without agitation. The non-105 
adhered cells were then washed with 1X PBS, the same volume of fresh medium 106 
was added, plates were covered with a breathable seal and biofilms were allowed to 107 
form for 48 h at 37oC with agitation (110 rpm) with a medium change after 24 hours. 108 
Antifungal treatment 109 
Media were carefully aspirated from the 48 h-old biofilms, without disrupting the 110 
biofilm structure. Biofilms were washed once with either 100 µL or 1 mL of 1x PBS,111 
respectively, and treated with a 100 µg/mL AMB solution in either RPMI or GHAUM 112 
for 24 hours at 37oC, statically. AMB solutions were prepared from an 8 mg/mL stock113 
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in DMSO, so that the final concentration of DMSO in a working solution did not 114 
exceed 1.25%. For control biofilms, corresponding amount of DMSO was added to115 
the medium instead of the antifungal solution. 116 
This step was either performed using the same volumes of antifungal solution as for117 
biofilm growth as described in (8) and (14) or increasing the volume of antifungal to 118 
fill the well up to the top (350 µL or 3 mL for 96- and 24-well plates, respectively).  119 
Clinical isolates were first treated with 64 µg/mL AMB solution. Strains giving rise to120 
colonies were then tested 5 times with 100 µg/mL AMB. 121 
Plating 122 
Upon 24 hours of antifungal treatment, AMB solution was aspirated and biofilms were123 
washed twice with 1X PBS prior to plating on YPD-agar plates. Biofilms were 124 
resuspended in 1x PBS/0.05% Tween-20. For the AMB-treated samples, the whole 125 
biofilms were plated. For control biofilms, serial dilutions were performed to allow126 
CFU counting. CFU were counted after incubating the plates at 30oC for 48 h.  127 
128 
RESULTS AND DISCUSSION 129 
In this work, we aimed to study the occurrence of persister cells in C. albicans 130 
biofilms. We applied the protocol published by LaFleur and colleagues, growing the 131 
biofilms in RPMI and in a 96-well plate format (8). We set up the protocol with 3 132 
C. albicans prototroph strains, namely SC5314, CEC369 and CEC4664 - prototroph133 
derivatives of BWP17 (22) and SN76 (23), respectively. BWP17 and SN76 are 134 
independent auxotroph derivatives of SC5314. 135 
We encountered a technical problem at the biofilm recovery step, usually performed 136 
by scraping the cells in 1x PBS and vortexing prior to plating (8, 14, 16, 24). In our137 
hands, the cells could not be properly resuspended and plated, as clumps of the138 
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biofilms would usually remain stranded inside the tips. Consequently, the CFU 139 
numbers obtained were highly variable for all samples, making any further analysis 140 
and comparison impossible (data not shown). 141 
We decided to test alternative approaches to circumvent the stickiness of biofilms. 142 
Resuspending cells in 20% glycerol/1X PBS for plating helped reducing stickiness, 143 
but did not improve consistency (data not shown). We hypothesized that EDTA might 144 
reduce adherence of biofilms by binding bivalent cations that are required for the 145 
activity of cell surface adhesins (25). Thus, we attempted applying 20% glycerol with146 
a range of EDTA concentrations (0, 50, 100 mM) for plating. 100 µL of EDTA147 
solutions of different concentrations were added to biofilms and left for 10 minutes at 148 
room temperature prior to biofilm disruption by scraping and vortexing. None of the149 
applied EDTA solutions allowed abolishing stickiness. Additionally, colonies growing 150 
on YPD-agar exhibited a wrinkled morphology, most probably linked to the toxicity of 151 
EDTA (26). Finally, we tried adding Tween-20 (0.05%) to PBS. Tween-20 eradicated152 
the problems of stickiness and poor disruption and improved recovery of cells from 153 
the biofilms (Fig. 1). The effect on cell viability was tested using a planktonic culture 154 
of SC5314 that was washed and plated on YPD-agar using PBS and PBS-Tween-20 155 
solutions. No impact on viability was observed (data not shown). Thus, in the 156 
experiments described below, biofilms were resuspended in a 0.05% Tween-20/1X 157 
PBS solution.  158 
However, even after this modification, the ratio of cells that survived AMB treatment159 
was still inconsistent between repeats. According to Lafleur and colleagues the ratios 160 
of C. albicans persister cells in biofilms vary from 0.1% to 2% for different strains,161 
notably from 0.05 to 0.1% for strain CAI4 – a derivative of C. albicans SC5314 (8).162 
Our values hardly ever exceeded 0.01% persisters per biofilm, even after improving 163 
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the recovery protocol, thus bordering with statistical error. We reasoned that 164 
increasing the surface of a biofilm and changing the growth media could improve 165 
persister yields and decided to test the protocol described in (14), applying the 166 
modifications that were mentioned previously. However, the problem of inconsistency167 
and low ratios of persisters remained (Fig. 2).  168 
In all protocols described previously, the volumes of the media and solutions used for169 
biofilm growth, washing, and AMB treatment were identical. Upon a careful 170 
observation, we noticed that C. albicans cells form a dense rim at the border of the 171 
air and liquid phases, as a result of agitation during growth. Treating a biofilm with the172 
exact same volume of antifungal and growth medium in static conditions thus could 173 
result in cells from the rim escaping treatment. We decided to increase the volume of 174 
the applied antifungal solution (filling wells to the top) and, to our surprise, this175 
change in the protocol led to a complete eradication of persisters for the laboratory 176 
strain SC5314 and its derivatives. Reproducibly, we did not get any persisters after177 
applying this change for all strains for both RPMI- and GHAUM-grown biofilms. Thus,178 
the volume of the antifungal applied in the original protocols for persister isolation179 
was skewing the results. Increasing the volume of antifungal eliminated this bias,180 
resulting in a complete eradication of any survivors after the antifungal treatment. 181 
In our work we used a modified protocol for persister cells isolation with a starting cell 182 
suspension of OD600 0.3 used for biofilm growth instead of 0.1 as described in the183 
original protocols (8, 14). To assess the impact of the initial cell number used for184 
seeding biofilms on persister cells’ appearance, we tested our protocol for SC5314185 
using cell suspensions of OD600 0.1, 0.3 and 0.5 for seeding. Regardless of the initial 186 
biomass, persister cells did not form in SC5314 biofilms grown either in RPMI or 187 
GHAUM (data not shown). 188 
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These results made us question the very existence of persister cells in C. albicans 189 
biofilms. Previously, Al-Dhaheri and Douglas showed that not all strains of 190 
C. albicans can form persister cells (17). Particularly, in their hands, SC5314 biofilms191 
lost all viability after exposure to 30 μg/mL AMB. However, biofilms of another clinical192 
isolate, GDH2346, appeared to contain a small proportion (0.01%) of cells that 193 
survived 100 μg/mL AMB treatment. These authors used a different in vitro model for 194 
assessing persistence, as they grew biofilms on silicone disks that were transferred 195 
to a new well filled with an antifungal solution. This prevented an escape of any cells196 
from the antifungal treatment. Thus, our modified protocol for treatment of biofilms 197 
formed in 96-well or 24-well plates corroborated the results obtained by the Douglas 198 
group for C. albicans strain SC5314 (17). 199 
Since the clinical isolate GDH2346 could give rise to survivors (17), we could not200 
exclude that persisters could emerge in biofilms of different C. albicans isolates.201 
Additionally in 2010, LaFleur and colleagues isolated and described C. albicans202 
strains from patients with long-term oral infection, that gave yield to increased levels 203 
of persisters (up to 8.9%) (24). These were called hip-mutants, by analogy with the 204 
high persister strains previously described for bacteria (27, 28). Although hip-mutants 205 
were identified using a protocol that showed limitations in our hands, we206 
hypothesized that some C. albicans clinical isolates could generally be more prone to207 
form persisters than others (namely SC5314). To test this assumption, we tested 95208 
clinical isolates (Table S1) for their ability to form biofilms and the occurrence of209 
persister cells following AMB treatment. In a first round of experiments, biofilms were 210 
treated with a 64 µg/mL AMB solution. Only 38 isolates (39.6%) displayed survivors211 
(notably, never exceeding a rate of 0.02%). According to the generally accepted212 
concept of persistence (10), the frequency of persisters’ appearance is independent 213 
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of the increase in antibiotic concentration. Thus in a second round of experiments, 214 
biofilms were developed for these 38 isolates and treated with a 100 µg/mL AMB215 
solution. Notably, only 7 isolates out of these 38 displayed survivors when grown with 216 
100 µg/mL AMB (CEC3622, CEC3668, CEC3669, CEC4514, CEC4521, CEC5317,217 
CEC5318). These 7 strains, together with 4 other isolates randomly picked in the 218 
remaining 31 strains (CEC712, CEC3708, CEC3711, CEC5316), were tested seven 219 
more times with 100 µg/mL of AMB. In most cases these strains did not yield 220 
persister cells (Fig. 3); however, 7 strains (CEC3622, CEC3669, CEC4514,221 
CEC4521, CEC5316, CEC5317 and CEC5318) gave rise to small numbers of 222 
survivors in one to four of the experiments (Fig. 3), with the survival rate never 223 
exceeding 9.1*10-4% per biofilm (for CEC3622). This could be explained either by the 224 
stochastic nature of persistence as a phenomenon or by technical errors during the 225 
experiment.  226 
We tested up to 30 randomly picked colonies for three isolates (CEC3622, CEC4514 227 
and CEC5316) on YNG medium containing 10 µg/mL of AMB. None of the tested 228 
colonies was able to grow in presence of amphotericin B (data not shown), proving 229 
that their survival was not a result of AMB resistance development. 230 
With an improved protocol in our hands, we decided to test other Candida species for 231 
their ability to form persister cells in biofilms. Previously, Al Dhaheri and Douglas (17)232 
reported that clinical isolates of C. krusei (Glasgow strain) and C. parapsilosis (AAHB 233 
4479) developed persister cells in biofilms (approximately 0.001% and 0.07%,234 
respectively) upon treatment with 100 µg/mL AMB. We selected 3 clinical isolates of 235 
C. tropicalis (CEC5296, CEC5297, CEC5298) and 3 of C. parapsilosis (CEC5299, 236 
CEC5300, CEC5301) from our lab collection to test with our protocol. One of the C.237 
tropicalis strains (CEC5298), as well as the 3 selected C. parapsilosis strains were 238 
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unable to grow as biofilms, and were excluded from the study. C. tropicalis CEC5296 239 
and CEC5297 formed proper biofilms, with a small fraction of persisters varying240 
between 2*10-5-6.4*10-3% and 2.3*10-7-2.6*10-4% respectively (data not shown). 241 
Such low values are comparable to the survival rates we observed for some of the C. 242 
albicans clinical isolates tested in this study. As before, we cannot exclude that these 243 
survivors are persister cells arising within C. tropicalis biofilms, or that they are the 244 
consequence of a technical error during the experiment. 245 
246 
CONCLUSION 247 
Since 1944, when Bigger first described persister cells in Staphylococcus (9), many248 
advances have been made in exploring this phenomenon, especially in bacteria. It is249 
known that microbial cultures growing in vivo can sometimes be very difficult to 250 
eradicate completely by an antibiotic treatment, causing relapses or development of 251 
chronic infections in patients. From an evolutionary point of view, a small pool of cells 252 
with the same genotype as the rest of the population but differing in their ability to253 
tolerate stress – including drug treatment – provides a form of insurance to the 254 
population. 255 
The phenomenon of persistence has not only been described for bacteria, but also in256 
other types of pathogens, and it has been proposed that persister cells significantly 257 
contributed to the recalcitrance of C. albicans biofilms to antifungal treatments (29–258 
31). 259 
C. albicans persister cells were first described in 2006 (8), and since then just a260 
handful of reports, sometimes contradictory, have been presented. In our study, we261 
explored standard protocols to obtain persisters, and showed that their proportion in 262 
biofilms formed by different C. albicans strains has been overestimated. Only Al-263 
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Dhaheri and Douglas did not detect persisters in SC5314 biofilms (17). In their study,264 
biofilms were grown on silicon discs that were transferred in antifungal solutions for265 
treatment. In contrast, the other published experiments were performed using 96-well 266 
plates and RPMI medium, or 24-well plates and SD-based medium, while keeping 267 
the incubation volumes constant throughout the experiment (8, 14–16). In this study,268 
we modified the latter protocols (8, 14–16) by increasing the volume of antifungal. 269 
This change led to the eradication of biofilms, indicating that previously detected 270 
“persisters” were likely the result of survival of cells that were not reached by the271 
antifungal. Our results corroborate the findings of Al-Dhaheri and Douglas (17). 272 
Notably, these authors were able to detect some persisters in biofilms of a clinical 273 
isolate (17), but the ratio obtained was much lower (0.01%) than the numbers 274 
published by others (8, 14). Although some of the clinical isolates of C. albicans and 275 
C. tropicalis tested in our study were occasionally able to yield survivors after the276 
treatment of biofilms with AMB, this phenomenon was rather inconsistent, pointing 277 
either to the stochastic nature of persistence itself, or another skew in the protocol 278 
while carrying out particular experiments. 279 
At this time, we cannot completely exclude the possibility of persistence in all C. 280 
albicans strains, though with the described protocol we managed to disprove their281 
presence for 92 C. albicans strains out of 98. It is important to stress that our results 282 
reflect only the behaviour of C. albicans biofilms grown in vitro; we cannot rule out 283 
that in the context of the host, persister cells could appear and contribute to the 284 
general resistance and dissemination of C. albicans. 285 
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FIGURE LEGENDS 427 
428 
Fig. 1 Effect of Tween 20 on the recovery of CFUs from C. albicans SC5314 429 
biofilms. C. albicans SC5314 was allowed to form biofilms in 100 μL RPMI in a 96-430 
well plate according to the protocol adapted from (8). Error bars: standard deviation431 
(SD) of 6 biological replicates generated from 2 independent experiments. # - non-432 
significant difference, *** - significant difference, p=0,0007 (unpaired t-test was 433 
applied to compare datasets). 434 
19 
435 
Fig. 2. Schemes of the protocols (A) and levels of persisters (B) obtained 436 
from biofilms grown using modified protocol from (14). Biofilms were grown in 1 437 
mL of GHAUM medium in 24-well plates before application of either 1 mL of AMB 438 
solution (on the left) or 3 mL of AMB solution (on the right). Ratios of surviving cells 439 
are as follow: SC5314 – 5.6*10-4%, CEC369 – 2.6*10-5%, CEC4664 – 9.4*10-5%. 440 
Error bars: SD of 6 biological replicates generated from 2 independent experiments. 441 
442 
443 
Fig. 3. Analysis of persister cell formation in 11 clinical isolates. Biofilms were444 
grown in 1 mL of GHAUM medium in 24-well plates, and treated with 3 mL of AMB 445 
solution (modified protocol from (14)). The values obtained from 7 biofilms were used446 
to draw the graph.  447 
448 
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TABLE 1. C. albicans reference strains used in this study 449 
STRAIN GENOTYPE REFERENCE 
SC5314 (18) 
CEC369 ura3::λimm434/ura3::λimm434 ARG4/arg4::hisG
HIS1/his1∆::hisG RPS1/RPS1::CIp10 
(19) 
CEC4664 ura3∆::λimm434/ura3∆::λimm434
iro1∆::λimm434/iro1∆::λimm434 ADH1/adh1::PTDH3-
carTA::SAT1 arg4Δ/ARG4 his1∆::hisG/HIS1 
RPS1/RPS1::CIp10 
Lab’s 
collection
450 
451 
TABLE 2. Clinical isolates used in this study 452 
NAME REFERENCE 
CEC704 (32) 
CEC712 (32) 
CEC718 (32) 
CEC723 (32) 
CEC1289 (33) 
CEC1424 (34) 
CEC2018 (35) 
CEC2019 (34) 
CEC2020 (36) 
CEC2021 (35) 
CEC2022 (37) 
CEC2871 (38) 
CEC2876 (38) 
CEC3494 (39) 
CEC3533 (37) 
CEC3534 (36) 
CEC3535 (36) 
CEC3536 (36) 
CEC3540 (32) 
CEC3541 (33) 
CEC3544 (39) 
CEC3547 (39) 
CEC3548 (39) 
CEC3549 (39) 
CEC3550 (40) 
CEC3553 (39) 
CEC3555 (33) 
CEC3556 (36) 
CEC3560 (34) 
CEC3561 (39) 
CEC3596 (33) 
CEC3611 (36) 
CEC3614 (36) 
CEC3615 (36) 
CEC3621 (32) 
CEC3622 (36) 
CEC3623 (32) 
21 
CEC3626 (39) 
CEC3627 (36) 
CEC3634 (36) 
CEC3637 (34) 
CEC3659 (35) 
CEC3662 (35) 
CEC3663 (32) 
CEC3664 (35) 
CEC3665 (35) 
CEC3668 (35) 
CEC3669 (35) 
CEC3672 (35) 
CEC3675 (35) 
CEC3681 (35) 
CEC3682 (35) 
CEC3685 (35) 
CEC3706 (35) 
CEC3708 (35) 
CEC3711 (35) 
CEC4035 (32) 
CEC4039 (32) 
CEC4103 (41) 
CEC4104 (41) 
CEC4106 (41) 
CEC4108 (41) 
CEC4256 (42) 
CEC4259 (42) 
CEC4481 (32) 
CEC4482 (32) 
CEC4485 (32) 
CEC4486 (32) 
CEC4487 (32) 
CEC4488 (32) 
CEC4489 (32) 
CEC4492 (32) 
CEC4494 (32) 
CEC4495 Lab’s collection 
CEC4496 (32) 
CEC4501 Lab’s collection 
CEC4504 Lab’s collection 
CEC4505 Lab’s collection 
CEC4511 Lab’s collection 
CEC4514 Lab’s collection 
CEC4515 Lab’s collection 
CEC4517 Lab’s collection 
CEC4521 Lab’s collection 
CEC4524 Lab’s collection 
CEC4526 (32) 
CEC4527 Lab’s collection 
CEC4547 Lab’s collection 
CEC4548 Lab’s collection 
CEC4549 Lab’s collection 
CEC4550 Lab’s collection 
CEC4552 (32) 
CEC5029 (32) 
22 
CEC5316 Lab’s collection 
CEC5317 Lab’s collection 
CEC5318 Lab’s collection 
453 



